Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lurasidone Hydrochloride

FDA-approved product (tablet, oral), marketed as Latuda, Lurasidone Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lurasidone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bipolar disorder
  • Bipolar I disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lurasidone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lurasidone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

    NCT00549666 · start 2007-08

    Registered record
    Registry ID
    NCT00549666
    Conditions
    Pharmacokinetics
    Interventions
    Lurasidone 40 mg; Placebo 40 mg; Ortho Tri-Cyclen
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-08
    Completion
    2007-12
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionLurasidone 40 mg; Placebo 40 mg; Ortho Tri-Cyclen
    PhasePhase 1
    Registry statusCompleted

  • A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

    NCT00088621 · start 2004-07

    Registered record
    Registry ID
    NCT00088621
    Conditions
    Schizophrenia
    Interventions
    Lurasidone 80mg tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-10
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone 80mg tablet
    PhasePhase 2
    Registry statusCompleted

  • A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

    NCT00088634 · start 2004-05

    Registered record
    Registry ID
    NCT00088634
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-05
    Completion
    2004-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Safety and Tolerability Study of Drug to Treat Schizophrenia

    NCT00044005 · start 2002-09

    Registered record
    Registry ID
    NCT00044005
    Conditions
    Schizophrenia
    Interventions
    Lurasidone 20 mg; Lurasidone 40 mg; Lurasidone 80mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09
    Completion
    2003-11
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone 20 mg; Lurasidone 40 mg; Lurasidone 80mg
    PhasePhase 2
    Registry statusCompleted

  • A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

    NCT00044044 · start 2002-07

    Registered record
    Registry ID
    NCT00044044
    Conditions
    Schizophrenia
    Interventions
    Lurasidone 20 mg; Lurasidone 40mg; Lurasidone 80 mg; Haloperidol 10mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-07
    Completion
    2003-05
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone 20 mg; Lurasidone 40mg; Lurasidone 80 mg; Haloperidol 10mg +1 more
    PhasePhase 2
    Registry statusCompleted